Pertuzumab-dpzb (Poherdy)
Dilution requiredFull monograph review pending
U.S. label preparation
Poherdy · Dilution required
- Preparation
- Use the 420 mg/14 mL IV vial. Add the prescribed volume to a bag containing 250 mL of 0.9% sodium chloride. Gently invert and avoid dextrose.
- Administration and handling
- Infuse the initial dose over 60 minutes. Subsequent doses may run over 30 to 60 minutes. Follow the label for observation after infusion.
Product and source details
Shanghai Henlius Biotech, Inc. · BLA761450
FDA labeling action 2025-11-13. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.